» Authors » C Bokemeyer

C Bokemeyer

Explore the profile of C Bokemeyer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 333
Citations 4856
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Brauneck F, Haag F, Woost R, Wildner N, Tolosa E, Rissiek A, et al.
Oncoimmunology . 2021 Jul; 10(1):1930391. PMID: 34211801
The inhibitory receptor TIGIT, as well as theectonucleotidases CD39 and CD73 constitute potential exhaustion markers for T cells. Detailed analysis of these markers can shed light into dysregulation of the...
12.
von Amsberg G, Sehovic M, Hartmann M, Bokemeyer C
Urologe A . 2021 Jun; 60(7):872-879. PMID: 34185119
Background: Rare tumors of the testis not originating from germinal epithelium are a diagnostic and therapeutic challenge. Objectives: To present current approaches in rare tumors of the testis using the...
13.
Aapro M, Lyman G, Bokemeyer C, Rapoport B, Mathieson N, Koptelova N, et al.
ESMO Open . 2021 Jan; 6(1):100038. PMID: 33421735
Cancer care has been profoundly impacted by the global pandemic of severe acute respiratory syndrome coronavirus 2 disease (coronavirus disease 2019, COVID-19), resulting in unprecedented challenges. Supportive care is an...
14.
Rammensee H, Loffler M, Walz J, Bokemeyer C, Haen S, Gouttefangeas C
Internist (Berl) . 2020 May; 61(7):690-698. PMID: 32462251
Tumor cells always exhibit differences to normal cells. These differences can be recognized by the immune system, enabling the destruction of tumor cells by T cells, as was impressively demonstrated...
15.
Waizenegger J, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, et al.
Leukemia . 2020 Mar; 34(9):2542. PMID: 32127637
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
16.
Salchow J, Mann J, Koch B, von Grundherr J, Jensen W, Elmers S, et al.
BMC Cancer . 2020 Jan; 20(1):16. PMID: 31906955
Background: Improved, multimodal treatment strategies have been shown to increase cure rates in cancer patients. Those who survive cancer as a child, adolescent or young adult (CAYA), are at a...
17.
Oing C, Skowron M, Bokemeyer C, Nettersheim D
Andrology . 2019 Mar; 7(4):487-497. PMID: 30924611
Background: Type II germ cell tumors represent the most common solid malignancy in men aged 15-45 years. Despite high cure rates of >90% over all stages, 10-15% of advanced patients...
18.
Schriefer P, Hartmann M, Oechsle K, Meyer C, Klutmann S, Fisch M, et al.
Urologe A . 2018 Oct; 58(4):418-423. PMID: 30374517
Background: Conventional radiographic imaging may fail to safely distinguish clinical stage I from stage IIA germ cell cancer, to localize isolated tumor marker relapses, and to equivocally identify the viability...
19.
Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascon P, Glaspy J, et al.
Ann Oncol . 2018 Oct; 29(Suppl 4):iv271. PMID: 30285221
No abstract available.
20.
Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, et al.
Ann Oncol . 2018 Aug; 29(8):1658-1686. PMID: 30113631
The European Society for Medical Oncology (ESMO) consensus conference on testicular cancer was held on 3-5 November 2016 in Paris, France. The conference included a multidisciplinary panel of 36 leading...